Elonox

Enoxaparin sodium biosimilar developed by Fresenius Kabi. Reference product Clexane (Lovenox in the United States).

Brands by market: Elonox (Canada) · Commercial partner or holder: Fresenius Kabi

FDAnot listed

EMAnot listed

PMDAnot listed

HCOct 2022approved

CDSCOnot listed

EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

PMDA

Japan

Not listed by PMDA.

Canada · Elonox

Health CanadaApproved

Brand

Elonox

Holder or applicant

Fresenius Kabi Canada LTD

Pathway

Biosimilar biologic drug (Notice of Compliance)

Approved

Oct 2022

Application or permission

DIN 02532247, 02532255, 02532263, 02532271, 02532298, 02532301, 02532328

Presentations

100, 30, 40, 60, 80 mg; 120, 150 mg

Note

Also Elonox Hp.

Source

S022

CDSCO

India

Not listed by CDSCO.

EDE

United Arab Emirates

Not listed by EDE.

Chronology

HCOct 2022Notice of Compliance, Health Canada

Sources

S022Health Canada, Drug Product Database data extract (active and inactive product files, biosimilar table) Primary (regulator)

All enoxaparin sodium biosimilars

Planning enoxaparin sodium biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Data current to September 2026.